ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has completed its acquisition of Coria Laboratories, Ltd., a privately-held specialty pharmaceutical company focused on dermatology products in the United States. Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, Inc., and other shareholders for $95 million.
